Related Experiment Video
Updated: Jul 12, 2026

Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles
Published on: August 2, 2016
Diffuse Erythematous Follicular Eruption Induced by Pegylated Liposomal Doxorubicin
Lingzhi Zhong1, Jian Hu1, Yuqing Hu1
1Department of Dermatology, Peking University People's Hospital, Beijing, People's Republic of China.
Abstract:
Pegylated liposomal doxorubicin (PLD) is a form of doxorubicin enclosed in pegylated liposomes and is associated with a high risk of mucocutaneous side effects. The most common cutaneous side effect is hand-foot syndrome, whereas other cutaneous reactions are rarely reported. The pathogenesis of PLD-induced cutaneous reaction is not yet clear. It is presumed that PLD could discharge through sweat or damaged vessels and impair keratinocytes in the basal layer or hair follicles as well as induce lymphocytic inflammation. We report a relatively rare of PLD-induced cutaneous reaction presented as diffuse follicular rashes and intertrigo-like dermatitis. A 56-year-old man, with leiomyosarcoma, developed pruritic and painful follicular erythematous papules with scaling on the trunk and limbs after receiving three cycles of PLD. The patient discontinued the use of PLD because of pain and exacerbation of the eruptions, and then the rashes gradually disappeared. This case highlights the potential pathogenesis underlying this unusual cutaneous reaction related to Pegylated Liposomal Doxorubicin.

